Nasdaq ardx.

Oct 18, 2023 · The FDA approved Ardelyx Inc's (NASDAQ:ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD ... On March 02, Ardelyx ( NASDAQ: ARDX ), now nearly a $800 million cap biopharmaceutical company reported 2022 financial results and provided a business update. Since the initial coverage, shares ...Sean Pavone/iStock via Getty Images. At a Glance. Navigating through robust quarterly sales, particularly from its flagship IBS-C product Ibsrela (tenapanor), Ardelyx (NASDAQ:ARDX) continues to ...Ardelyx, Inc. Reports Employment Inducement Grants. WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover... WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Ardelyx Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ARDX updated stock price target summary.

WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...

Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and ...Principal Financial Group Inc. acquired a new stake in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 24,269 shares of the biopharmaceutical company’s stock, valued at approximately $82,000. …The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ...16 thg 8, 2021 ... Ardelyx (NASDAQ:ARDX) is trading higher today on below-average volume despite a loss of over 5% on Friday after the company announced worse ...Complete Ardelyx Inc. stock information by Barron's. View real-time ARDX stock price and news, along with industry-best analysis.

Ardelyx (ARDX) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.31 per share a year ago. These figures are ...

Ardelyx Inc (NASDAQ:ARDX) trade information. Upright in the red during last session for losing -0.39%, in the last five days ARDX remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $3.86 price level, adding 6.76% to its value on the day.

Who is on Ardelyx's Insider Roster? The list of insiders at Ardelyx includes David M. Mott, David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell, and Susan Rodriguez. Learn more on insiders at ARDX.WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced upcoming data presentations for tenapanor for hyperphosphatemia at the …Ardelyx ( NASDAQ: ARDX) shares spiked ~10% on Tuesday after the developer of gastrointestinal and cardiorenal therapies soundly beat Wall Street expectations with its Q3 2023 financials, thanks ...Ardelyx Inc (NASDAQ:ARDX) trade information. Instantly ARDX has showed a red trend with a performance of -1.60% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.49 on Monday, 11/27/23 increased the stock’s daily price by 4.01%.WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Citigroup Inc. decreased its position in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 49.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the ...Find the latest Financials data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.

WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Find the latest Institutional Holdings data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.The chain sheet shows the price, volume and open interest for each option strike price and expiration month. Nasdaq provides call and put options information of stocks. Financial analysts and ...Ardelyx (NASDAQ: ARDX), a biotech innovator, is arguably one of the best picks among penny stocks to buy.Its powerful portfolio, featuring IBSRELA for IBS-C and XPHOZAH for chronic kidney disease ...From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ... WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...

Ardelyx, Inc. (NASDAQ: ARDX): $3.63 per Share. Ardelyx is a biopharmaceutical company focused on developing and commercializing drug candidates that address significant unmet medical needs. Its current product takes a novel approach to treating irritable bowel syndrome. Pipeline products include a small-molecule therapy for …Dec 13, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ...

25 thg 8, 2023 ... Cantor Fitzgerald, by way of analyst Louise Chen, upgraded Ardelyx to “overweight” in light of a very strong potential win. The analysts expect ...XPeng Inc. American depositary shares, each representing two Class A ordinary shares (XPEV) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global ...Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Nasdaq has halted trading of the Company's common stock.WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx (NASDAQ:ARDX) is a great speculative biotech play to look into. Why is that? That's because despite its potential with two drugs in the pipeline, the stock is still trading with a very low ...WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx, Inc. Reports Employment Inducement Grants. WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover... 25 thg 9, 2023 ... Ardelyx's (NASDAQ:ARDX) Kidney Disease Therapy Bags Approval in Japan ... Ardelyx's lead candidate, tenapanor, has bagged approval in Japan for ...The US FDA has accepted an NDA resubmission from Ardelyx ( NASDAQ: ARDX) for Xphozah (tenapanor) as a chronic kidney disease treatment. The agency determined the application is subject a a class 2 ...

Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ...

Complete Ardelyx Inc. stock information by Barron's. View real-time ARDX stock price and news, along with industry-best analysis.

WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ...Back to ARDX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following …Free Trial NASDAQ:ARDX Ardelyx (ARDX) Earnings Date, Estimates & Call Transcripts $4.31 -0.01 (-0.23%) (As of 04:25 PM ET) Compare Today's Range $4.20 …Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Nasdaq has halted trading of the Company's common stock.WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...(NASDAQ: ARDX) Ardelyx currently has 232,137,709 outstanding shares. With Ardelyx stock trading at $4.51 per share, the total value of Ardelyx stock (market …Ardelyx, Inc. Common Stock (ARDX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor for adult patients with CKD on dialysis with hyperphosphatemia. The company will host a conference call on December 29, 2022, at 8:00 AM ET. To participate in the conference call, please call (866) 374-5140 (toll-free) or (404) 400-0571 (toll) and …

14 thg 9, 2023 ... Fintel reports that on September 13, 2023, Wedbush reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Outperform recommendation.08 Jun, 2020, 16:01 ET. FREMONT, Calif., June 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX ), a specialized biopharmaceutical company focused on developing innovative first-in-class ...Nov 17, 2023 · ARDELYX INC ( ARDX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ... Instagram:https://instagram. sblgxvbilx stockget funded to trade stocks300 slr mercedes benz Ardelyx (NASDAQ:ARDX) is a biopharmaceutical innovator specializing in renal and cardiovascular care, driving novel therapeutic solutions forward.The stock has consistently shown a positive ...The latest price target for Ardelyx ( NASDAQ: ARDX) was reported by HC Wainwright & Co. on Wednesday, November 1, 2023. The analyst firm set a price target for 11.00 expecting ARDX to rise to ... uber nyseweight watchers international stock Oct 18, 2023 · The FDA approved Ardelyx Inc's (NASDAQ:ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD ... oilu stock price The forecasts range from a low of 6.06 to a high of $12.60. The average price target represents an increase of 81.50% from its latest reported closing price of 4.73. leaderboard of companies with ...Oct 17, 2023 · WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...